BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mohanty A, Salameh S, Butt AA. Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection. Curr HIV/AIDS Rep 2019;16:389-94. [PMID: 31482299 DOI: 10.1007/s11904-019-00466-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Nakagawa M, Asahina Y, Kakinuma S, Okamoto R. Impact of eradication of hepatitis C virus on liver-related and -unrelated diseases: morbidity and mortality of chronic hepatitis C after SVR. J Gastroenterol 2022. [PMID: 36585501 DOI: 10.1007/s00535-022-01940-1] [Reference Citation Analysis]
2 Sparvoli JMH, Sparvoli AC, Dumith SDC, Pereira AA, Paula ALMD, Garcia L, Belarmino V, Hora VPD, Martínez AMBD, Gonçalves CV. Impact of hepatitis C virus eradication with direct-acting antivirals on glycidic metabolism. Archives of Endocrinology and Metabolism 2022. [DOI: 10.20945/2359-3997000000543] [Reference Citation Analysis]
3 Salama II, Raslan HM, Abdel-Latif GA, Salama SI, Sami SM, Shaaban FA, Abdelmohsen AM, Fouad WA. Impact of direct-acting antiviral regimens on hepatic and extrahepatic manifestations of hepatitis C virus infection. World J Hepatol 2022; 14(6): 1053-1073 [DOI: 10.4254/wjh.v14.i6.1053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Toma L, Dodot M, Zgura A, Bacalbasa N, Silaghi A, Simu R, Isac T, Mercan-Stanciu A. Calprotectin in viral systemic infections-COVID-19 versus hepatitis C virus. Clin Exp Med 2022;22:311-7. [PMID: 34254197 DOI: 10.1007/s10238-021-00743-7] [Reference Citation Analysis]
5 Scelza G, Amato A, Pagano AM, Matteis G, Caruso R, Scelza A, Sisalli L, Biasi S, Marigliano F, Gagliardi M, Martina S, Iandolo A. Effect of hepatitis C antiviral therapy on oral lichen planus and hyposalivation in inmates. Ann Gastroenterol 2022;35:74-9. [PMID: 34987292 DOI: 10.20524/aog.2021.0672] [Reference Citation Analysis]
6 Freekh DA, Helmy MW, Said M, El-Khodary NM. The effect of direct acting antiviral agents on vascular endothelial function in Egyptian patients with chronic hepatitis C virus infection. Saudi Pharm J 2021;29:1120-8. [PMID: 34703365 DOI: 10.1016/j.jsps.2021.08.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Schlevogt B, Boeker KHW, Mauss S, Klinker H, Heyne R, Link R, Simon KG, Sarrazin C, Serfert Y, Manns MP, Wedemeyer H. Weight Gain after Interferon-Free Treatment of Chronic Hepatitis C-Results from the German Hepatitis C-Registry (DHC-R). Biomedicines 2021;9:1495. [PMID: 34680612 DOI: 10.3390/biomedicines9101495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
8 Cacciola I, Russo G, Filomia R, Pitrone C, Caccamo G, Giandalia A, Alibrandi A, Stella Franzè M, Porcari S, Maimone S, Saitta C, Squadrito G, Raimondo G. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis. Liver Int 2021;41:2059-67. [PMID: 33894103 DOI: 10.1111/liv.14905] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
9 Kitab B, Kohara M, Tsukiyama-kohara K. Host-Targeting Antivirals for Treatment of Hepatitis C. Advances in Hepatology 2021. [DOI: 10.5772/intechopen.95373] [Reference Citation Analysis]
10 Sicras-Mainar A, Morillo-Verdugo R. Potential interactions between pangenotypic direct-acting antivirals and concomitant cardiovascular therapies in patients with chronic hepatitis C virus infection. J Int Med Res 2020;48:300060520964659. [PMID: 33111612 DOI: 10.1177/0300060520964659] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Su F, Cogan CJ, Bendich I, Zhang N, Whooley MA, Kuo AC. Hepatitis C infection and complication rates after total shoulder arthroplasty in United States veterans. JSES Int 2021;5:699-706. [PMID: 34223418 DOI: 10.1016/j.jseint.2021.02.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
13 Sagnelli E, Sagnelli C, Russo A, Pisaturo M, Camaioni C, Astorri R, Coppola N. Impact of DAA-Based Regimens on HCV-Related Extra-Hepatic Damage: A Narrative Review. Adv Exp Med Biol 2021;1323:115-47. [PMID: 33326112 DOI: 10.1007/5584_2020_604] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
14 Hsiao YH, Chen WM, Chang CH, Chen MY. Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy. J Adv Nurs 2021;77:3370-8. [PMID: 33818822 DOI: 10.1111/jan.14850] [Reference Citation Analysis]
15 Butt AA, Yan P, Kapadia S, Abou-Samra AB, Janjua NZ, Ibrahim S. Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use. Sci Rep 2021;11:5883. [PMID: 33723313 DOI: 10.1038/s41598-021-85283-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Villani R, Romano AD, Sangineto M, Serviddio G. Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease. Intern Emerg Med 2021;16:1239-45. [PMID: 33471254 DOI: 10.1007/s11739-020-02628-1] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
17 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Rev Gastroenterol Hepatol 2020;14:579-90. [PMID: 32613874 DOI: 10.1080/17474124.2020.1776111] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Khan MU, Mahmoud MI, Butt AA. Hepatitis c virus and chronic kidney disease. Expert Review of Gastroenterology & Hepatology 2020;14:579-90. [DOI: 10.1080/17474124.2020.1776111] [Reference Citation Analysis]
19 Winston A, Wurcel AG, Gordon C, Goyal N. Viral hepatitis in patients on hemodialysis. Semin Dial 2020;33:254-62. [PMID: 32394502 DOI: 10.1111/sdi.12882] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Dash S, Aydin Y, Widmer KE, Nayak L. Hepatocellular Carcinoma Mechanisms Associated with Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment. J Hepatocell Carcinoma 2020;7:45-76. [PMID: 32346535 DOI: 10.2147/JHC.S221187] [Cited by in Crossref: 38] [Cited by in F6Publishing: 42] [Article Influence: 12.7] [Reference Citation Analysis]